Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Semaglutide vs Retatrutide: A Simple Research Comparison

Semaglutide vs Retatrutide: A Simple Research Comparison

Jun 11, 2026 4 min GLP-1 / Metabolic
TL;DR
Semaglutide is a well-studied GLP-1 receptor agonist with multiple large phase 3 trials behind it. Retatrutide is a newer, triple-receptor agonist that showed striking early results in a phase 2 trial. Both are research-use-only peptides, and dosing protocols differ significantly between them.

What Are These Two Peptides?

Let's start simple. Both Semaglutide and Retatrutide are synthetic peptides studied for their effects on body weight and metabolism. That's where the similarities start to diverge.

Semaglutide mimics a hormone called GLP-1 (glucagon-like peptide-1). Your gut releases GLP-1 after you eat. It tells your brain you're full and nudges your pancreas to manage blood sugar. Semaglutide copies that signal — but lasts much longer in the body.[6]

Retatrutide is newer and more ambitious. It hits three hormone receptors at once: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon. Researchers call it a "triple agonist." The idea is that targeting all three pathways together may produce stronger metabolic effects than targeting just one.[4]

What Does the Research Actually Show?

Semaglutide has a deep evidence base. The STEP 2 phase 3 trial tested a 2.4 mg weekly dose in adults with overweight or obesity and type 2 diabetes. Participants lost an average of 9.6% of their body weight over 68 weeks, compared to 3.4% with placebo.[1] A separate phase 3 trial in an East Asian population (STEP 6) found even larger reductions — around 13.2% body weight loss at the same 2.4 mg weekly dose.[2] A systematic review confirmed these weight-loss findings hold up across multiple studies in people without diabetes too.[5]

Retatrutide is earlier in its research journey. A 2023 phase 2 trial in The New England Journal of Medicine tested doses ranging from 1 mg up to 12 mg weekly. At the highest dose, participants lost a mean of around 17.5% of body weight over 24 weeks — a result that caught the scientific community's attention.[4] Phase 3 trials are ongoing. That means the evidence base is thinner, but the early signal is strong.

How Do Research Doses Differ?

This is where researchers need to pay close attention. The two peptides are dosed very differently in published protocols.

  • Semaglutide research typically uses a slow escalation up to 2.4 mg once weekly via subcutaneous injection. Escalation usually starts at 0.25 mg and steps up over several weeks to reduce GI side effects.[1][6]
  • Retatrutide phase 2 research used weekly subcutaneous doses ranging from 1 mg to 12 mg, also with a gradual escalation schedule. The highest doses produced the most weight loss but also more side effects.[4]
  • Both peptides showed gastrointestinal side effects (nausea, vomiting, diarrhea) as the most common adverse events — mostly mild to moderate in trials.[3][4]

Use our calculator to explore how research escalation schedules are structured for each peptide side by side.

Quick Comparison at a Glance

  • Mechanism: Semaglutide = 1 receptor (GLP-1); Retatrutide = 3 receptors (GLP-1, GIP, glucagon)
  • Evidence stage: Semaglutide = multiple phase 3 trials completed; Retatrutide = phase 2 completed, phase 3 ongoing
  • Research dose range: Semaglutide up to 2.4 mg/week; Retatrutide up to 12 mg/week in phase 2
  • Weight loss in trials: Semaglutide ~9–13% body weight; Retatrutide ~17% at highest dose (early data)
  • Side effect profile: Both show GI effects as most common; severity increases with dose

How Do You Choose What to Read About?

If you're researching a peptide with an extensive published record and well-documented dosing protocols, Semaglutide has the deeper literature. Multiple large trials have mapped its behavior in diverse populations.[1][2][5]

If you're interested in cutting-edge research into triple-receptor mechanisms and want to follow an emerging story, Retatrutide is the more novel read. The phase 2 data is genuinely striking, but it's early-stage science.[4]

Neither peptide should be confused with a consumer product or medical treatment recommendation. All dosing information here is sourced from peer-reviewed clinical research and is presented for educational purposes only. Always consult a qualified healthcare professional for any medical decisions.

Sources

  1. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. — Lancet (London, England), 2021. PMID 33667417.
  2. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. — The lancet. Diabetes & endocrinology, 2022. PMID 35131037.
  3. Safety of Semaglutide. — Frontiers in endocrinology, 2021. PMID 34305810.
  4. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. — The New England journal of medicine, 2023. PMID 37366315.
  5. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. — Journal of the ASEAN Federation of Endocrine Societies, 2022. PMID 36578889.
  6. Wegovy (semaglutide): a new weight loss drug for chronic weight management. — Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022. PMID 34706925.
See the dosage chart — Semaglutide
A GLP-1 receptor agonist widely studied for metabolic and weight outcomes.
Semaglutide

FAQ

What is the main difference between semaglutide and retatrutide?
Semaglutide activates one hormone receptor (GLP-1), while retatrutide activates three: GLP-1, GIP, and glucagon. This triple-action approach is what makes retatrutide a newer area of intense research interest. Semaglutide has far more completed large-scale trials behind it, giving researchers a much larger body of safety and dosing data to work from.
What doses were used in semaglutide research trials?
Phase 3 trials like STEP 2 used a target dose of 2.4 mg once weekly via subcutaneous injection, reached through a gradual escalation starting at 0.25 mg. This slow ramp-up was designed to reduce gastrointestinal side effects. Researchers in East Asian populations used similar escalation protocols with comparable results at the same top dose.
How much weight loss did retatrutide show in phase 2 research?
In a 2023 phase 2 trial published in The New England Journal of Medicine, participants receiving the highest retatrutide dose (12 mg weekly) lost a mean of approximately 17.5% of body weight over 24 weeks. This is notable compared to other peptides studied, though phase 3 trials are still underway to confirm these findings in larger, longer studies.
Are the side effects of semaglutide and retatrutide similar?
Yes, both peptides show gastrointestinal side effects — nausea, vomiting, and diarrhea — as the most commonly reported adverse events in research trials. These were mostly described as mild to moderate in severity. For semaglutide, gastrointestinal issues were reported in up to 63% of participants at the 2.4 mg dose in one trial, generally decreasing after the escalation phase.
For research and educational use only. Not medical advice.